Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
$0.24
-0.7%
$0.63
$0.22
$3.00
$2.49M1.181.21 million shs3.99 million shs
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.05
+1.5%
$0.97
$0.81
$1.76
$24.72M0.74127,086 shs93,685 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.44
+0.6%
$3.16
$2.57
$6.88
$21.44M0.639,025 shs3,426 shs
Promis Neurosciences stock logo
PMN
Promis Neurosciences
$0.50
+2.5%
$0.54
$0.47
$2.37
$16.34M-0.0879,303 shs24,315 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
0.00%-46.71%-67.10%-67.70%-81.18%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
0.00%+11.17%+5.56%0.00%-18.99%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%-0.03%+4.85%-11.59%-44.53%
Promis Neurosciences stock logo
PMN
Promis Neurosciences
0.00%-3.85%-4.76%-22.48%-68.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
3.1458 of 5 stars
3.85.00.00.01.80.01.3
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.2637 of 5 stars
3.75.00.00.02.90.80.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.6713 of 5 stars
0.03.00.00.01.51.70.6
Promis Neurosciences stock logo
PMN
Promis Neurosciences
1.4564 of 5 stars
3.52.00.00.00.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
3.50
Strong Buy$8.003,247.28% Upside
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.33
Buy$10.00856.94% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
3.00
Buy$4.50800.00% Upside

Current Analyst Ratings Breakdown

Latest ADIL, ENLV, NAII, and PMN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Promis Neurosciences stock logo
PMN
Promis Neurosciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$3.00
4/21/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
4/3/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
4/1/2025
Promis Neurosciences stock logo
PMN
Promis Neurosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
3/24/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$6.00 ➝ $7.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/AN/AN/AN/A$0.64 per shareN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/A$1.00 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/AN/AN/AN/A$0.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
-$13.20M-$1.46N/AN/AN/AN/A-218.88%-177.61%8/12/2025 (Estimated)
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
$2.78M-$0.05N/AN/AN/AN/A-186.19%-98.56%8/7/2025 (Estimated)

Latest ADIL, ENLV, NAII, and PMN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q1 2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.16-$0.15+$0.01-$0.15N/AN/A
5/14/2025Q1 2025
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
-$0.50-$0.34+$0.16-$0.34N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/12/2025Q1 2025
Promis Neurosciences stock logo
PMN
Promis Neurosciences
-$0.14-$0.21-$0.07-$0.21N/AN/A
3/31/2025Q4 2024
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.16-$0.23-$0.07-$0.23N/AN/A
3/31/2025Q4 2024
Promis Neurosciences stock logo
PMN
Promis Neurosciences
-$0.14-$0.02+$0.12-$0.02N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/A
1.99
1.99
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/A
7.20
7.20
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/A
3.36
3.36
CompanyEmployeesShares OutstandingFree FloatOptionable
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
2010.44 million9.99 millionNo Data
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
7023.65 million20.75 millionOptionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Promis Neurosciences stock logo
PMN
Promis Neurosciences
532.69 million30.69 millionNot Optionable

Recent News About These Companies

ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year
ProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trial

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adial Pharmaceuticals stock logo

Adial Pharmaceuticals NASDAQ:ADIL

$0.24 0.00 (-0.67%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$0.25 +0.01 (+4.18%)
As of 06/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Enlivex Therapeutics stock logo

Enlivex Therapeutics NASDAQ:ENLV

$1.04 +0.02 (+1.46%)
Closing price 06/18/2025 03:54 PM Eastern
Extended Trading
$1.04 0.00 (-0.48%)
As of 06/18/2025 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.44 +0.02 (+0.56%)
Closing price 06/18/2025 03:58 PM Eastern
Extended Trading
$3.47 +0.03 (+0.87%)
As of 06/18/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Promis Neurosciences stock logo

Promis Neurosciences NASDAQ:PMN

$0.50 +0.01 (+2.46%)
Closing price 06/18/2025 03:50 PM Eastern
Extended Trading
$0.50 0.00 (0.00%)
As of 06/18/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.